Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Caterina Vivaldi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9307-2326; OpenAlex author ID A5037539040, A5083016242. Sources: OpenAlex.

Their work

Papers
27 (first author 5, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
99
Papers, trials and grants by year

2016: 3 papers · 2017: 1 paper · 2018: none · 2019: 5 papers · 2020: 3 papers · 2021: 7 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 3 papers

Papers 27

  1. Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter, observational PANCAKE study. Co-author DOI 10.1016/j.esmogo.2025.100276↗
  2. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  3. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
  4. A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemothe… Co-author DOI 10.1016/j.dld.2025.11.007↗
  5. Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score… Co-author DOI 10.1016/j.esmoop.2025.105874↗
  6. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Co-author DOI 10.1016/j.ejca.2023.04.012↗
  7. Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. Co-author DOI 10.3390/cancers15030900↗
  8. In Pancreatic Adenocarcinoma Alpha-Synuclein Increases and Marks Peri-Neural Infiltration. Co-author DOI 10.3390/ijms23073775↗
  9. Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection. Co-author DOI 10.1007/s13304-020-00883-7↗
  10. Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-p… Co-author DOI 10.1038/s41397-020-00203-7↗
  11. Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/biom11060780↗
  12. Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. First author DOI 10.3390/cancers13153738↗
  13. Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers13164131↗
  14. Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). Co-author DOI 10.3390/curroncol28030164↗
  15. Detailing the ultrastructure's increase of prion protein in pancreatic adenocarcinoma. Co-author DOI 10.3748/wjg.v27.i42.7324↗
  16. First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? Co-author DOI 10.1016/j.ejca.2020.06.031↗
  17. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. Co-author DOI 10.1177/1758835920947970↗
  18. Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications. First author DOI 10.3389/fonc.2020.00064↗
  19. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Co-author DOI 10.1016/j.clcc.2019.08.004↗
  20. FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer. Reply. Co-author DOI 10.1056/nejmc1900712↗
  21. Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Performance Status of 2: Lights and Shadows of … Last author DOI 10.1200/jco.19.00127↗
  22. The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. First author DOI 10.2217/pgs-2018-0149↗
  23. Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Coh… Co-author DOI 10.3390/cancers11070939↗
  24. Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. First author DOI 10.1038/s41598-017-08297-z↗
  25. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors. Co-author DOI 10.1002/ijc.30125↗
  26. Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'. Co-author DOI 10.1038/bjc.2016.69↗
  27. Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. First author DOI 10.2217/fon.16.16↗

Closest collaborators

The 25 strongest of 99 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Enrico Vasile · 18 shared papers, 2016–2026 · strength 1.85
  2. Lorenzo Fornaro · 14 shared papers, 2016–2023 · strength 1.35
  3. Monica Niger · 5 shared papers, 2023–2026 · strength 0.89
  4. Mario Scartozzi · 4 shared papers, 2023–2026 · strength 0.75
  5. Giampaolo Tortora · 4 shared papers, 2021–2026 · strength 0.71
  6. Silvia Catanese · 7 shared papers, 2016–2021 · strength 0.62
  7. Andrea Pretta · 3 shared papers, 2025–2026 · strength 0.59
  8. Federico Nichetti · 3 shared papers, 2025–2026 · strength 0.57
  9. Lisa Salvatore · 3 shared papers, 2025–2026 · strength 0.55
  10. Elisa Giommoni · 3 shared papers, 2021–2026 · strength 0.47
  11. Irene Pecora · 4 shared papers, 2019–2021 · strength 0.39
  12. Letizia Procaccio · 2 shared papers, 2025–2026 · strength 0.38
  13. Eleonora Rofi · 4 shared papers, 2017–2021 · strength 0.38
  14. Marzia Del Re · 4 shared papers, 2017–2021 · strength 0.38
  15. Romano Danesi · 4 shared papers, 2017–2021 · strength 0.38
  16. Francesco Leone · 3 shared papers, 2019–2025 · strength 0.38
  17. Carolina Sciortino · 2 shared papers, 2025–2026 · strength 0.37
  18. Francesca Bergamo · 2 shared papers, 2025–2026 · strength 0.36
  19. Giuseppe Aprile · 2 shared papers, 2023–2026 · strength 0.35
  20. Sara Lonardi · 2 shared papers, 2023–2026 · strength 0.34
  21. Gregorio Di Franco · 3 shared papers, 2021–2022 · strength 0.33
  22. Luca Morelli · 3 shared papers, 2021–2022 · strength 0.33
  23. Guido Giordano · 2 shared papers, 2021–2026 · strength 0.31
  24. Niccola Funel · 3 shared papers, 2019–2021 · strength 0.30
  25. Daniela Campani · 3 shared papers, 2019–2021 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.